

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Del Carmen Jeffrey</u> <hr/> (Last) (First) (Middle) 355 ALHAMBRA CIRCLE SUITE 1250 <hr/> (Street) CORAL FL 33134 GABLES <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 06/23/2020	3. Issuer Name and Ticker or Trading Symbol <u>CATALYST PHARMACEUTICALS, INC. [CPRX]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) _____ <u>Chief Commercial Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Options to purchase Common Stock	(1)	08/06/2025	Common Stock	150,000	2.86	D
Options to purchase Common Stock	(2)	12/19/2025	Common Stock	40,000	2.24	D
Options to purchase Common Stock	(3)	01/06/2027	Common Stock	30,000	4.21	D
Options to purchase Common Stock	(4)	06/23/2027	Common Stock	150,000	4.7	D
Restricted Stock Units	(5)	(5)	Common Stock	30,000	(6)	D

Explanation of Responses:

- Options have vested or will vest in five equal tranches on August 6, 2019, 2020, 2021, 2022 and 2023.
- Options have vested or will vest in three equal tranches on December 19, 2019, 2020 and 2021.
- Options will vest in three equal tranches on January 6, 2021, 2022 and 2023.
- Options will vest in five equal tranches on June 23, 2021, 2022, 2023, 2024 and 2025.
- Derivative security will vest in three equal tranches on June 23, 2021, 2022 and 2023.
- Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.

/s/ Jeffrey Del Carmen

07/02/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.